- /
- Supported exchanges
- / US
- / SLGL.NASDAQ
Sol Gel Technologies Ltd (SLGL NASDAQ) stock market data APIs
Sol Gel Technologies Ltd Financial Data Overview
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Sol Gel Technologies Ltd (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Sol Gel Technologies Ltd data using free add-ons & libraries
Get Sol Gel Technologies Ltd Fundamental Data
Sol Gel Technologies Ltd Fundamental data includes:
- Net Revenue: 1 795 K
- EBITDA: -17 690 000
- Earnings Per Share: -5
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Sol Gel Technologies Ltd Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-08-20
- EPS/Forecast: -2.31
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sol Gel Technologies Ltd News
New
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $1.01 per share a year ago. T...
New Strong Buy Stocks for October 16th
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Ultrapar Participações S.A. UGP: This energy and infrastructure company has seen the Zacks Consensus Estimate for its curren...
Supernus Pharmaceuticals (SUPN) Matches Q2 Earnings Estimates
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.54 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.91 per share a year ago. These figures ...
Bausch Health (BHC) Q2 Earnings and Revenues Beat Estimates
Bausch Health (BHC) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.9 per share a year ago. These figures ...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.